Risk factors for PFS: univariable and multivariable Cox regression analyses
| . | . | PFS (univariable) . | PFS (multivariable) . | ||||
|---|---|---|---|---|---|---|---|
| Variables . | Category . | Hazard ratio . | CI . | P . | Hazard ratio . | CI . | P . |
| Age | ≤70 y | 1 | — | .028 | — | — | — |
| >70 y | 2.48 | 1.11-5.56 | |||||
| Sex | Male | 1 | — | .197 | — | — | — |
| Female | 0.69 | 0.40-1.21 | |||||
| ISS | 1 | 1 | — | — | — | — | — |
| 2 | 1.14 | 0.56-2.32 | .712 | ||||
| 3 | 1.22 | 0.61-2.46 | .577 | ||||
| Serum creatinine | <2 mg/dL | 1 | — | .544 | — | — | — |
| ≥2 mg/dL | 0.79 | 0.37-1.69 | |||||
| Myeloma isotype | IgG | 1 | — | — | — | — | — |
| IgA | 0.77 | 0.38-1.57 | .472 | ||||
| Light chains | 1.15 | 0.56-2.36 | .700 | ||||
| Cytogenetic risk | SR | 1 | — | .001 | 1 | — | .011 |
| HR | 3.81 | 1.73-8.39 | 3.69 | 1.35-10.10 | |||
| Induction scheme | Others | 1 | — | — | — | — | — |
| PI-based | 0.15 | 0.02-1.12 | .151 | ||||
| IMiD-based | 1.05 | 0.56-1.95 | .148 | ||||
| IMiD+PI | 0.81 | 0.25-1.65 | .810 | ||||
| ASCT | No prior ASCT | 1 | — | .137 | — | — | — |
| Prior ASCT | 0.62 | 0.33-1.17 | |||||
| Consolidation treatment | No consolidation | 1 | — | .280 | — | — | — |
| Consolidation | 0.34 | 0.46-2.44 | |||||
| PET* | PET+ | 1 | — | <.001 | 1 | — | .007 |
| PET− | 0.16 | 0.06-0.41 | 0.07 | 0.01-0.48 | |||
| MRD* | MRD+ | 1 | — | .013 | 1 | — | .027 |
| MRD− | 0.49 | 0.27-0.86 | 0.30 | 0.10-0.87 | |||
| . | . | PFS (univariable) . | PFS (multivariable) . | ||||
|---|---|---|---|---|---|---|---|
| Variables . | Category . | Hazard ratio . | CI . | P . | Hazard ratio . | CI . | P . |
| Age | ≤70 y | 1 | — | .028 | — | — | — |
| >70 y | 2.48 | 1.11-5.56 | |||||
| Sex | Male | 1 | — | .197 | — | — | — |
| Female | 0.69 | 0.40-1.21 | |||||
| ISS | 1 | 1 | — | — | — | — | — |
| 2 | 1.14 | 0.56-2.32 | .712 | ||||
| 3 | 1.22 | 0.61-2.46 | .577 | ||||
| Serum creatinine | <2 mg/dL | 1 | — | .544 | — | — | — |
| ≥2 mg/dL | 0.79 | 0.37-1.69 | |||||
| Myeloma isotype | IgG | 1 | — | — | — | — | — |
| IgA | 0.77 | 0.38-1.57 | .472 | ||||
| Light chains | 1.15 | 0.56-2.36 | .700 | ||||
| Cytogenetic risk | SR | 1 | — | .001 | 1 | — | .011 |
| HR | 3.81 | 1.73-8.39 | 3.69 | 1.35-10.10 | |||
| Induction scheme | Others | 1 | — | — | — | — | — |
| PI-based | 0.15 | 0.02-1.12 | .151 | ||||
| IMiD-based | 1.05 | 0.56-1.95 | .148 | ||||
| IMiD+PI | 0.81 | 0.25-1.65 | .810 | ||||
| ASCT | No prior ASCT | 1 | — | .137 | — | — | — |
| Prior ASCT | 0.62 | 0.33-1.17 | |||||
| Consolidation treatment | No consolidation | 1 | — | .280 | — | — | — |
| Consolidation | 0.34 | 0.46-2.44 | |||||
| PET* | PET+ | 1 | — | <.001 | 1 | — | .007 |
| PET− | 0.16 | 0.06-0.41 | 0.07 | 0.01-0.48 | |||
| MRD* | MRD+ | 1 | — | .013 | 1 | — | .027 |
| MRD− | 0.49 | 0.27-0.86 | 0.30 | 0.10-0.87 | |||
IMiD, immunomodulatory drug; PI, proteasome inhibitor.
For these variables, the results of PET and MRD at maximal response were examined.